Leading Brazilian Information Security Specialist Kryptus Expands Its Activities in the EMEA Region
12.5.2020 17:55:00 EEST | Business Wire | Press release
Seeking to consolidate its presence and develop new businesses in Europe, Middle East and Africa (EMEA), Brazilian Kryptus, specialized in cryptography and information security, announces the expansion of its international activities with the opening of a new unit of the company in Switzerland. The initiative is focused on offering technical support in the region, as well as develop the market, regional channel partners, and respond to local requirements. The move includes the announcement of Thierry Martin as the new director for EMEA and the head of the Swiss branch.
With a strong cybersecurity background, Martin is an engineer who has led several different technology companies in Europe and Brazil. The executive has also been a member of the Kryptus board in 2016 and 2017.
Currently providing solutions to financial institutions, private companies, and governments around the globe, Kryptus aims through this expansion to reach more customers with its competitive and unique product portfolio. The offerings include kNET, its high-performance HSM with unbreakable encryption, and Commguard, its flexible line of link encryptors.
"Kryptus can deliver world-class, trustworthy, and secure cryptography solutions for critical applications. Our presence in the region allows the optimization of services for customized or custom-developed products, providing a strong value proposition in the EMEA region," says Thierry Martin.
According to Roberto Gallo, founder & CEO of Kryptus, expanding to the EMEA region strengthens the company's position as a strategic provider of cyberdefense for governments and enterprises. "Kryptus can now extend its technology offering to Europe, Middle East, and Africa, based on relevant certifications and high performance," he points out.
With its Headquarter in Campinas, Kryptus was founded in 2003 and counts among its customers companies like BSH (a BOSCH Gmbh subsidiary), Claro Brasil (America Móvil Group), Certisign (exclusive Verisign partner in Brazil), Iron Mountain, iFood and Embraer. Granted the status of Strategic Defense Company (EED) by the Brazilian Defense Council, Kryptus has gained the trust - as a supplier from a neutral country - of several government agencies to protect their sovereignty. Among such customers with the highest security requirements, Kryptus delivered government-grade solutions to the Peruvian Navy, the Colombian Army and the Brazilian Army, Air Force, Navy, Intelligence Agency, Ministry of Foreign Affairs, and Superior Electoral Court, as well as to several other governments.
About Thierry Martin
Thierry Martin was born in Switzerland where he studied Electronics and Computer Science. He has professional experience in various areas of technology, among them Digital TV, Cyber Security, Electronics, and Telecommunications. Along his career he has lived and worked in Switzerland, Spain, the United Kingdom, and Brazil, as well as worked extensively with the United States and Asia. He has held executive positions in companies like Nagra, Kudelski Security, Selectron Systems AG, and Mouvent AG.
About Kryptus
Kryptus is a provider of solutions in Information Security. With 17 years of history and HQ in Campinas (SP), Kryptus SA is an independent Brazilian company that has been growing consistently for the past 10 years, focusing on long term actions, scientific and technological plans, and understanding the mission of its clients in the business lines it develops. Kryptus is a partner of the Kudelski Group. Kryptus is a Brazilian Strategic Defense Company (EED), a status granted by the Brazilian Defense Council.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005624/en/
Contact information
Thierry Martin
+41 79 932 19 23
thierry.martin@kryptus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom